



THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Ryuichi Morishita et al.

**Application No.:** 09/869,475

**Filed:** October 10, 2001

**Confirmation No.:** 4309

**For:** GENE THERAPY FOR DIABETIC ISCHEMIC DISEASE

**Examiner:** Brian Whiteman

**Art Unit:** 1635

**Attorney Reference No.:** 6235-59221-01

**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV514604036US in an envelope addressed to: MAIL STOP RCE, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent for Applicant(s)

Date Mailed July 13, 2004

MAIL STOP RCE  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(4)**


Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing of a first Office action after the filing of a request for continued examination. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.


Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By   
Susan Alpert Siegel, Ph.D.  
Registration No. 43,121

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

cc: Docketing



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Attorney Docket Number</b>	6235-59221-01
	<b>Application Number</b>	09/869,475
	<b>Filing Date</b>	October 10, 2001
	<b>First Named Inventor</b>	Ryuichi Morishita
	<b>Art Unit</b>	1635
	<b>Examiner Name</b>	Brian Whiteman

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Kala <i>et al.</i> , "Angiogenesis und Vaskulogenes," <i>Hertz</i> 25:611-622, 2000 (English abstract)
		Li <i>et al.</i> , "Technology evaluation: gene therapy (FGF-5), Vical," <i>Curr. Opin. Molec. Therap.</i> 1:260-5, 1999
		Morishita <i>et al.</i> , "Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy," <i>Hypertension</i> 33:1379-1384, 1999
		Prud'homme and Chang, "Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon gamma receptor/IgG1 fusion protein," <i>Gene Therapy</i> 6:771-7, 1999
		Rochlitz, "Gene Therapy of Cancer," <i>Drugs of Today</i> 36:619-629, 2000
		Udea <i>et al.</i> , "Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart," <i>Ann. Thorac. Surg.</i> 67:1726-31, 1999.

EXAMINER SIGNATURE:	DATE CONSIDERED:
---------------------	------------------

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.